There’s tremendous anecdotal evidence that microdosing has therapeutic benefits, yet there’s limited research on its effects. Luckily, that’s starting to change thanks to Diamond Therapeutics.
The Toronto-based company received Health Canada approval to conduct a Phase 1 human clinical trial to evaluate low doses of psilocybin in up to 80 healthy volunteers. The preclinical research suggests that low, non-hallucinogenic doses have potential therapeutic benefits.
Diamond Therapeutics is also planning to conduct a Phase 2 trial in the US and Canada to evaluate low psilocybin doses in treating anxiety and will support an investigator-led study on moderate depression as well.